drug

Second Generation Antipsychotics (SGA)

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Neurocrine Biosciences
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
Stable Schizophrenia

Trials

1
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
NCT03319953Phase 2Completed

KOLs & investigators

1
Medical Director Clinical Science

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Neurocrine Biosciences
company
trial
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
PHASE2
trial
indication
Stable Schizophrenia
indication
KOL
Medical Director Clinical Science
KOL score —
person